How does lacosamide's impact on sodium channels lower blood pressure?

Lacosamide blocks voltage-gated sodium channels in a use-dependent way, but it does not lower blood pressure. Clinical data show no meaningful effect on blood pressure in patients treated for epilepsy or neuropathic pain.

How does lacosamide act on sodium channels?
Lacosamide stabilizes the inactivated state of voltage-gated sodium channels, slowing recovery from inactivation. This reduces the ability of neurons to fire repetitive action potentials at high frequency. The effect occurs mainly in over-active neurons, leaving normal neuronal signaling largely intact.

Why does the sodium-channel block not translate to blood-pressure changes?
Cardiac and vascular smooth-muscle cells rely on different sodium-channel subtypes (Nav1.5 in heart, Nav1.7/1.8 in sensory neurons) and on calcium and potassium channels for contraction and vascular tone. Lacosamide’s selectivity for neuronal sodium channels is high enough that it does not meaningfully alter cardiac conduction or vascular smooth-muscle contractility at therapeutic doses.

What clinical evidence supports the absence of blood-pressure effects?
Pooled analyses of pivotal trials (SPM 927, SP755, SP756) and post-marketing surveillance report no consistent change in systolic or diastolic blood pressure versus placebo. Mean changes remain within 1–2 mmHg and are statistically indistinguishable from control groups. Regulatory reviews by the FDA and EMA list no blood-pressure warnings in the approved labeling.

Are there reports of blood-pressure changes in special populations?
Isolated case reports describe transient hypotension during rapid intravenous loading in intensive-care settings, but these events coincide with concurrent sedatives or sepsis rather than a direct lacosamide effect. In patients with pre-existing hypertension or on antihypertensives, no clinically relevant interactions have been documented.

When might blood-pressure monitoring still be advised?
During intravenous loading doses above 200 mg or in patients receiving other sodium-channel blockers (e.g., class-I antiarrhythmics), routine vital-sign checks are recommended because additive effects on cardiac conduction, not blood pressure, remain the primary concern.